Emulate Revenue and Competitors

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Emulate's estimated annual revenue is currently $32.5M per year.(i)
  • Emulate received $36.0M in venture funding in June 2018.
  • Emulate's estimated revenue per employee is $193,750
  • Emulate's total funding is $224.3M.

Employee Data

  • Emulate has 168 Employees.(i)
  • Emulate grew their employee count by 4% last year.

Emulate's People

Co-Founder, CTOReveal Email/Phone
CEOReveal Email/Phone
VP, Platform DevelopmentReveal Email/Phone
Senior Director, Applied BioScienceReveal Email/Phone
Director Commercial OperationsReveal Email/Phone
Associate Director Product ManagementReveal Email/Phone
Associate Director Quality AssuranceReveal Email/Phone
Director Lab OperationsReveal Email/Phone
Associate Director, Applied BioSciencesReveal Email/Phone
Director, Discovery BiologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Emulate?

We work at the intersection of biology, engineering, and design, developing technologies that emulate human biology. Our products are enabling a new era of precision medicine and the development of applications for personalized health. Our Human Emulation System, which uses Organs-on-Chips technology, is being used by industry, government, and academia to understand how different diseases, medicines, chemicals and foods affect human health. The system offers researchers a new standard for predicting human response - with greater precision and control than today's cell culture or animal-based experimental methods. We are also leading a bold, new precision medicine initiative with our clinical partners. Named "Patient-on-a-Chip," the program is developing personalized chips with patients' own cells. This initiative will help transform the way each of us understands our own bodies and manages our own health. Research conducted using our Organ-Chips has been published in high-impact scientific journals, including Science. In addition, Organ-Chips have been acquired by the Museum of Modern Art (MoMA) in New York for their permanent collection, and have also been awarded Product Design of the Year 2015 by London's Design Museum. Our founding team pioneered the original Organs-on-Chips technology during their residency within the Wyss Institute for Biologically Inspired Engineering at Harvard University.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Emulate News

2022-04-20 - Erik ten Hag tipped to emulate Johan Cruyff after being appointed Manchester United manager

The new United manager is being backed to follow in the footsteps of some Ajax legends ahead of his arrival at Old Trafford.

2022-04-20 - Why Sony (Probably) Won't Emulate the PS3 - IGN

PS Now and the new PS Plus won't allow PS3 games to be downloaded, only streamed. We dig into why.

2022-04-17 - Extraterrestrial mining would emulate 'tears of wine' phenomenon

Tears of wine is a phenomenon frequently observed as a ring of wine formed near the top of the glass generates droplets that fall back into...

2021-09-07 - Emulate Closes $82 Million Series E Financing to Scale Amid Rapid Growth in Organ-on-a-Chip Market

Emulate, Inc., a leading provider of next generation in vitro models, today announced the close of an $82 million Series E financing round led by existing investor Northpond Ventures with additional participation from Perceptive Advisors. With this investment, Emulate has raised nearly $225 mill ...

2021-09-07 - Emulate Raises $82M in Series E Funding

Emulate, Inc., a Boston, MA-based provider of next generation in vitro models, closed an $82m Series E financing round. The round, which brought total funding raised to date to nearly $225m, was led by existing investor Northpond Ventures with participation from Perceptive Advisors. The compan ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Emulate Funding

DateAmountRoundLead InvestorsReference
2016-03-29$28.0MBOS FundArticle
2018-06-20$36.0McFounders FundArticle